Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Systemic treatment of hormone receptor-positive (HR+) breast cancer is undergoing a renaissance, with a number of targeted therapies including CDK4/6, mTOR, and PI3K inhibitors now approved for use in combination with endocrine therapies. The increased use of targeted therapies has changed the natur...

Full description

Bibliographic Details
Main Authors: Allegra Freelander, Lauren J. Brown, Andrew Parker, Davendra Segara, Neil Portman, Brandon Lau, Elgene Lim
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Genes
Subjects:
biomarkers
breast cancer
estrogen receptor
prognostic
predictive
pharmacodynamic
Online Access:https://www.mdpi.com/2073-4425/12/2/285

Internet

https://www.mdpi.com/2073-4425/12/2/285

Similar Items